Korean push into biotech space meant to challenge China, as ViroMed buys US plant for new gene-therapy development. High risk/reward bet, only for the brave.
The News: ViroMed Co. Ltd., the Korean biotech, has seen companies miss out on approvals for novel therapies because the FDA had problems with their manufacturing processes. With its first treatment… Read more »